Blood protein predictors of brain amyloid for enrichment in clinical trials?
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood‐based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large‐scale prevention trials. Methods: Nontargeted proteomic discovery was applied to 78 subjects from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing with a range of NAB values. Technical and independent replications were performed by immunoassay. Results: Seventeen discovery candidates were selected for technical replication. α2‐Macroglobulin, fibrinogen γ‐chain (FGG), and complement factor H‐related protein 1 were confirmed to be associated with NAB. In an independent cohort, FGG plasma levels combined with age predicted NAB had a sensitivity of 59% and specificity of 78%. Conclusion: A single blood protein, FGG, combined with age, was shown to relate to NAB and therefore could have potential for enrichment of clinical trial populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“The availability of longer lived [18] F- labeled Ab PET tracers, such as flutemetamol [8] and florbetapir [9] could foster wider usage in the clinic [10].”
BackgroundCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“This inspection should demonstrate considerable evidence of the classical pathological hallmarks of AD; extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles predominantly comprised of hyperphosphorylated Tau [1].”
BackgroundImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“(11)C-Pittsburgh compound B (PiB), coupled with positron emission tomography (PET), is widely used in research in measuring in vivo Ab deposition, because its uptake in AD correlates with Ab plaques measured neuropathologically in the same brains [7].”
BackgroundLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
ApoE-4 and Age at Onset of Alzheimer's Disease: The NIMH Genetics Initiative
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C. P., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.139 · Cited by 479 · cited 1×
“APOE status is a substantial risk factor for AD [41] and amyloid [30,42].”
BackgroundRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“Some, but not all [14,15], studies have also shown that amyloid deposition as measured using PiB-PET either predicts a decline in cognitive measures or tracks with such declines [2,16].”
BackgroundRyu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406 · cited 2×
“FGG is normally rejected from the brain by the bloodbrain barrier (BBB), yet has still been detected in mice and human brain tissue [45,46].”
BackgroundCortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., Bhuvanendran, S., Fenz, K. M., & Strickland, S. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.014 · Cited by 339
Paul, J., Strickland, S., & Melchor, J. P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070304 · Cited by 319
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · cited 5×
“Scans were visually rated as PiB+ or PiB- by an experienced single rater blinded to clinical and plasma data [13].”
BackgroundMethodInfluentialSelf-citationJohnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 1×
“The endophenotype approach is increasingly being adopted, for example, to study blood-based biomarkers of cognitive decline [23,24], apolipoprotein E ε4 (APOE ε4) carrier status [25], brain atrophy [26,27], and hippocampal metabolism [28].”
MethodSelf-citationSong, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034078 · Cited by 214 · cited 1×
“The endophenotype approach is increasingly being adopted, for example, to study blood-based biomarkers of cognitive decline [23,24], apolipoprotein E ε4 (APOE ε4) carrier status [25], brain atrophy [26,27], and hippocampal metabolism [28].”
MethodPlasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
Kiddle, S. J., Thambisetty, M., Simmons, A., Riddoch-Contreras, J., Hye, A., Westman, E., Pike, I., Ward, M., Johnston, C., Lupton, M. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044260 · Cited by 100 · cited 3×
“TheAPOE ε4 allele is a substantial risk factor for AD [41] and amyloid [30,42].”
BackgroundResultSelf-citationEffect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype
Thambisetty, M., An, Y., Nalls, M., Sojkova, J., Swaminathan, S., Zhou, Y., Singleton, A. B., Wong, D. F., Ferrucci, L., Saykin, A. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.015 · Cited by 90
Xu, G., Zhang, H., Zhang, S., Fan, X., & Liu, X. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01268.x · Cited by 89
Cited by
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Self-citationFibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
Metadata
- Authors
- Ashton, N. J., Kiddle, S. J., Graf, J., Ward, M., Baird, A. L., Hye, A., Westwood, S., Wong, K. V., Dobson, R. J., Rabinovici, G. D., Miller, B. L., Rosen, H. J., Torres, A., Zhang, Z., Thurfjell, L., Covin, A., Hehir, C. T., Baker, D., Bazenet, C., Lovestone, S., & AIBL Research Group
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-03
- Volume
- 1
- Issue
- 1
- Pages
- 48-60
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W1976942091
- Cited by
- 54
- References
- 18
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.